COVID and Coagulation

Abstract Number: PB0186

A Weight-based Approach to Thromboprophylaxis Dosing for Medical Inpatients with COVID-19

R. Price¹, Z. Kirkham^1,2, A. Szuman¹, S. Ahmed³, C. Macaulay⁴, K. Talks⁵, B. Greystoke⁵, K. Musgrave^2,5

Abstract Number: PB0190

ACE2, ACE and Thromboinflammation in COVID-19

A. Lundström¹, L. Ziegler¹, S. Havervall¹, A.-S. Rudberg¹, F. Von Meijenfeldt², T. Lisman², N. Mackman³, P. Sandén¹, C. Thålin¹

Abstract Number: PB0299

Acute Liver Necrosis in a Sars-Cov-2 Positive Patient with Triple Positive Antiphospholipid Syndrome

V. La Mura^1,2, R. Gualtierotti^1,3, I. Martinelli¹, B. Ferrari¹, A.M. Ierardi⁴, N. Bitto¹, G. Ghigliazza¹, A. Giachi¹, M. Maggioni⁵, M. Cugno^1,3, A.L. Fracanzani^3,6, G. Carrafiello^4,7, F. Peyvandi^1,3

Abstract Number: PB0168

Adjusting D-dimer to Lung Disease Extent to Exclude Pulmonary Embolism in COVID-19 Patients (Co-LEAD)

L. Khider¹, B. Planquette¹, A. Le Berre², S. Soudet³, G. Pernod⁴, R. Le Mao⁵, M. Besutti⁶, N. Gendron¹, A. Yannoutsos², D.M. Smadja¹, G. Goudot¹, T. Mirault¹, E. Messas¹, J. Emmerich², F. Couturaud⁵, G. Ferretti⁴, M.-A. Sevestre³, N. Meneveau⁶, G. Chatellier¹, O. Sanchez¹

Abstract Number: PB0270

After the Storm; 6-month Follow up Outcomes and Management of COVID-19 Related Venous Thromboembolism

M. Ahmed¹, R. Khan¹, E. Xenou¹, M. Fowler¹, S. Sinha¹, A. Lokare¹, C. Kartsios¹

Abstract Number: PO129

Alterations of the Coagulation Profile in Peruvians Admitted for Pneumonia due to SARS-COV2: Cross-sectional Study

R. Pichardo Rodriguez^1,2, W. Peña-Oscuvilca¹, L. Cordova-Cueva³, O. Ruiz-Franco², F. Garmendia-Lorena²

Abstract Number: OC 15.2

Altered Platelet Proteome and Platelet-leukocyte Interactions in Patients with COVID-19

L. Goudswaard¹, C. Williams¹, F. Hamilton², D. Arnold², A. Davidson¹, A. Poole¹, I. Hers¹

Abstract Number: PB0159

Altered Protein S Activity Contributes Significantly to COVID-19 Pro-thrombotic State

T. Nguyen¹, D. Melancon¹, M. Dean², A. Zea³, S. Chatterjee¹, J. Harman¹, V. Pilli¹, R. Nossaman⁴, J. Ochoa⁴, A. Ochoa², R. Majumder¹

Abstract Number: PB0300

Analysing Risk Factors for Thrombosis in Covid-19 and Cancer Patients

B. Obispo Portero¹, J. Rogado¹, G. Serrano¹, C. Pangua¹, A. Lopez¹, A. Martin¹, M. Perez¹, M.A. Lara¹

Abstract Number: PB0204

Anemia and Enhancement of Coagulation Are Associated during Severe COVID-19 Infection

T. Helin¹, M. Lemponen¹, T. Lahtiharju¹, R. Lassila², L. Joutsi-Korhonen¹

Abstract Number: PB0280

Anti-coagulant Drugs among Moderate, Severe and Critically Ill COVID 19 Patients in the Second Referral Hospital in Surabaya

P.Z. Romadhon¹, S.D. Suryantoro¹, C. Windradi¹, B.A. Mahdi¹, E.D. Agustin¹, D. Novendrianto¹, K.N. Widiastuti¹, M. Savitri¹, P.N.A. Amrita¹, M Noordiansyah¹, S. YB¹, A. Ashariati¹

Abstract Number: PB0184

Anti-factor Xa Activity after Intermediate Dose Nadroparin for Thrombosis Prophylaxis in Critically Ill COVID-19 Patients with and without Acute Kidney Injury

R. Eck¹, J. van Leur², M. Lukens¹, W. Bult¹, R. Gans¹, K. Meijer¹, F. Keus¹

Abstract Number: OC 70.2

Anti-thrombotics and Anti-hypertensives with Direct Action against SARS-CoV-2

M. Brennan¹, A. Chubb¹

Abstract Number: PB0262

Anticoagulant Response to Tailored Low Molecular Weight Heparin Regimens in Patients with COVID-19 Infection

A. Artoni¹, V. De Zan¹, M. Boscarino¹, C. Novembrino¹, E. Scalambrino¹, S. Aliberti², M. Panigada³, I. Martinelli¹, A. Tripodi¹, F. Peyvandi^1,4

Abstract Number: PB0202

Anticoagulation Strategies and Risk Of Bleeding Events in Critically ill COVID-19 Patients

C. Gabara¹, B. Solarat², P. Castro^1,3, S. Fernández^1,3, J.R. Badia², D. Toapanta⁴, S. Schulman⁵, J.C. Reverter⁶, A. Soriano⁷, J. Moises², J. Aibar¹

Abstract Number: PB0230

Anticoagulation with Tinzaparin in COVID-19 Patients in ICU: Are Low Anti-Xa Levels Associated with the Development of Thrombo-embolic Events?

R. Van Lancker¹, S. Demeester², K. Jochmans², M. Mekeirele¹

Abstract Number: PB0247

Apparent Different of Lupus Anticoagulant Disappearance in Novel Coronavirus 2019 Patients as a Distinct Clinical Feature

H. Kim¹, M.-S. Kim², S. Jang¹

Abstract Number: PB0173

Are Mild or Moderate COVID-19 Patients at Higher Risk of VTE? A Comparison of Two Prospective European Cohorts in Emergency Departments

D. Douillet^1,2, J. Riou^3,4, A. Penaloza⁵, T. Moumneh^1,2, C. Soulié⁶, D. Savary^1,7, F. Morin¹, R. Mahieu^8,9, P.-M. Roy^1,2

Abstract Number: PB0249

Artificial Neural Networks to Predict Covid-19 Progression of Moderate Hospitalized Patients using Early Clinical Parameters and Blood Tests

T.D. Martins¹, S.D. Martins², S.A.L. Montalvão², G.Y. Ottaiano¹, M. Al Bannoud¹, L.Q. Silva², S.C. Huber², T.S. Diaz³, C.K. Wroclawski⁴, C.C. Filho⁴, R.M. Filho⁵, J.M. Annichino-Bizzacchi²

Abstract Number: PO127

Association between FGB – 455 G/A and PAI-1 – 675 5G / 4G Gene Polymorphisms and Covid-19 Severity

B. Vatseba¹, N. Virstyuk¹